Fig. 2From: Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?Box plots of percentage changes (in relation to baseline) of haemoglobin (A), platelet count (PLT) (B) and white blood cell count (WBC) (C), at second cycle and at restaging, among patients with disseminated or diffuse metastatic bone involvement (PROMISE) categorised by biochemical response behaviour (PCWG3)Back to article page